Last reviewed 2026-04-23 · How we verify

FlF/VI + Tiotropium

FlF/VI is a fixed-dose combination of fluticasone furoate and vilanterol (long-acting beta-2 agonist and inhaled corticosteroid) combined with tiotropium (long-acting muscarinic antagonist) to provide multi-mechanism bronchodilation and anti-inflammatory effects in chronic obstructive pulmonary disease.

FlF/VI is a fixed-dose combination of fluticasone furoate and vilanterol (long-acting beta-2 agonist and inhaled corticosteroid) combined with tiotropium (long-acting muscarinic antagonist) to provide multi-mechanism bronchodilation and anti-inflammatory effects in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Mechanism of action

The combination delivers three complementary mechanisms: fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, vilanterol provides bronchodilation through beta-2 adrenergic receptor agonism, and tiotropium provides additional sustained bronchodilation via muscarinic M3 receptor antagonism. This triple therapy approach targets multiple pathways to improve airflow obstruction and reduce exacerbations in COPD patients.

Approved indications

• Chronic obstructive pulmonary disease (COPD) maintenance therapy

Common side effects

• Tremor
• Headache
• Palpitations
• Oral candidiasis
• Upper respiratory tract infection

Key clinical trials

• Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.